Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SARS-CoV-2 3CL protease, also known as the main protease (Mpro) or 3-chymotrypsin-like protease, is a highly conserved cysteine hydrolase essential for coronavirus replication. It is responsible for the proteolytic processing of two large viral polyproteins (pp1a and pp1ab), which are translated from the viral RNA genome. This processing releases non-structural proteins (nsps) that are crucial for viral transcription, replication, and recombination. Without functional 3CLpro activity, coronaviruses cannot replicate or produce new virions; thus, it plays an indispensable role in their life cycle. It is a major focus area for drug development due to its high selectivity potential, and several inhibitors have already been discovered through high-throughput screening.
Inhibition of viral polyprotein processing
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SARS-CoV-2 3CL Protease (3CLpro).